新型素纳作为粉样β聚合抑制剂
Ahmed A Hefny1,2, Kartar Singh1, Rahul C Karuturi1
1School of Pharmacy, Health Sciences Campus, University of Waterloo, 200 University Avenue West, Waterloo, Ontario N2L 3G1, Canada.
ACS medicinal chemistry letters
|April 16, 2025
概括
新型N-基色氨酸化合物在抑制粉样β (Aβ42) 聚合方面表现有前途,这是阿尔茨海默病的关键因素. 这些化合物还具有抗氧化和分解性质,提供了潜在的治疗策略.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 生物化学 生物化学
背景情况:
- 粉样β (Aβ42) 聚合是阿尔茨海默病的中心病理标志.
- 开发有效的Aβ42聚合抑制剂对于治疗干预至关重要.
研究的目的:
- 设计,合成和评估新型的N-基色氨酸衍生物作为Aβ42聚合的抑制剂.
- 评估这些化合物的分解和抗氧化特性.
- 调查它们在降低Aβ42中介细胞毒性方面的潜力.
主要方法:
- 合成N-基色氨酸酶衍生物.
- 基于提奥夫拉T的光测定用于监测Aβ42聚合动力学.
- 基于细胞的测试来评估细胞毒性.
- 计算建模以了解相互作用的机制.
主要成果:
- 化合物8i和8j显示出Aβ42聚合的显著抑制 (∼91%),与白醇和甲基蓝相比.
- 这两种化合物都表现出Aβ42分解 (高达76%) 和抗氧化活性 (高达80.5%).
- 化合物8i和8j在细胞培养中降低了Aβ42介导的细胞毒性.
- 计算研究表明Aβ42体通道内的相互作用,稳定了组件.
结论:
- N-基色氨酸衍生物是Aβ42聚合的有效抑制剂.
- 这些化合物具有多方面的治疗潜力,包括分解和抗氧化作用.
- 在阿尔茨海默氏症治疗中,N-基索酶是向粉样蛋白级联的有希望的候选者.
更多相关视频
相关概念视频
01:22Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
03:03Amyloid Fibrils
9.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.1K
01:23Antidepressant Drugs: MAOIs and Other Agents
164
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
164